Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes
Zeidan A, Hendrick F, Friedmann E, Gore S, Baer M, Sasane M, Paley C, McNally D, Davidoff A. Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes. Blood 2012, 120: 426. DOI: 10.1182/blood.v120.21.426.426.Peer-Reviewed Original ResearchIron chelation therapyErythropoiesis-stimulating agentsMarginal structural modelsRisk of deathMyelodysplastic syndromeRenal diseaseTransfusion thresholdThyroid diseaseIron overloadChelation therapyObservation periodHealth statusOral iron chelation therapyICD-9-CM diagnosisICD-9-CM codesOlder MDS patientsSolid tumor diagnosisDuration of therapyCo-morbid conditionsOnset of diabetesEnd of studyOverall survival analysisPatients' health statusReduced mortality riskDrug side effects